Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score matched cohort study

摘要

Aims In heart failure with reduced ejection fraction (HFrEF), renin angiotensin system inhibitors (RASi) improve morbidity and mortality. However, patients aged 80 years constituted a small minority in trials. We assessed the association between RASi use and mortality/morbidity in HFrEF patients aged 80 years.